Health Care
Viewpoints
Filter by:
Mintz/ML Strategies Pharmacy Summit White Paper Highlights Drug Development Process
June 7, 2016 | Blog
The pharmaceutical industry is facing the prospect of a rapidly evolving landscape, one that challenges its regulatory understanding and business model.
Read more
States Step Up Efforts on Drug Pricing Initiatives
June 6, 2016 | Blog | By Carrie Roll
A few months ago, we noted that states were jumping into the drug pricing fray largely driven by a lack of federal action and a rising tide of public discontent.
Read more
No More Bidding - CMS 2, EGWPs 1
June 2, 2016 | Blog | By Tara E. Dwyer
Under the new payment methodology, EGWPs will no longer be paid based on their bid and applicable benchmark, rather they will be paid an amount established by comparing non-EGWP bids to the applicable benchmark (all adjusted for location, Star Ratings, and risk scores). This change was proposed for 2017, but CMS delayed the full implementation until 2018.
Read more
Study Finds Widespread HIPAA Violations Occurring on Yelp
June 2, 2016 | Blog
It is no secret that the Health Insurance Portability and Accountability Act (HIPAA) is a trap for the unwary. A recent study by the non-profit ProPublica has uncovered that the online review site Yelp (as well as other rating sites) are making it easier for covered entities to be ensnared.
Read more
Research Opens a Door for Disability Policy
June 2, 2016 | Blog
One of the challenges of policy making is that bills must go before the Congressional Budget Office (CBO). CBO has one of the toughest jobs in Washington. Their job is to dispassionately look at policy and evaluate the cost of the bill to the federal treasury. Sometimes that means splashing cold water on the high-minded aspirations of policy makers.
Read more
FTC Wins Stay of Pennsylvania Hospital Merger Pending Appeal in Third Circuit
May 26, 2016 | Blog | By Dionne Lomax
The Third Circuit granted on Tuesday the Federal Trade Commission’s (“FTC”) request for an injunction pending appeal of the proposed merger between Penn State Hershey Medical Center and Pinnacle Health System.
Read more
Check Your Inbox: OCR Continues to Verify Entity Contact Information for Phase 2 HIPAA Audits
May 23, 2016 | Blog
Covered Entities need to continue to check their inboxes for emails from the HHS Office for Civil Rights (“OCR”) requesting verification of contact information in connection with Phase 2 of the HIPAA Audit Program. OCR previously indicated that Covered Entities would begin to receive verification emails in May.
Read more
Recap: 2016 Mintz/ML Strategies Pharmacy Industry Summit
May 19, 2016 | Blog | By Theresa Carnegie
The pharmacy industry is under increasing scrutiny from all angles. Whether at the legislative or agency level, Washington as well as many states seem intent on addressing perceived issues surrounding drug pricing, reimbursement and program integrity.
Read more
FDA Releases Draft Guidance for 3D Printed Medical Devices
May 17, 2016 | Blog | By Joanne Hawana
On May 10, 2016, FDA released its first draft guidance for medical device manufacturers who are using additive manufacturing (AM), commonly referred to as 3D printing.
Read more
OIG Issues Favorable GPO Advisory Opinion
May 16, 2016 | Blog | By Ryan Cuthbertson
The OIG recently issued a favorable advisory opinion permitting a health system (the “Health System”) to become the sole owner of a Group Purchasing Organization (“GPO”), some of whose members were also owned by the Health System (the “Proposed Arrangement”).
Read more
FTC Granted 2-Week Reprieve in Effort to Block Pennsylvania Hospital Merger
May 13, 2016 | Blog
The Federal Trade Commission (“FTC”) and the state of Pennsylvania have two weeks to persuade the Court of Appeals for the Third Circuit that the pending merger of Penn State Hershey Medical Center (“Hershey”) and Pinnacle Health System (“Pinnacle”) is anti-competitive.
Read more
Alternative Payment Models (APMs) Under MACRA Proposed Rule
May 6, 2016 | Blog | By Lauren Moldawer
Continuing our blog series on CMS’s massive proposed rule for the implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), we dedicate this post to examining the Advance Payment Model (APM) provisions of the proposed rule.
Read more
Four Days Until The Mintz/ML Strategies Pharmacy Industry Summit
May 6, 2016 | Blog | By Theresa Carnegie
Here in Washington, it seems everyone has an idea on a drug “fix”: amendments to the provisions governing Medicare reimbursement, new rebate requirements, changes to price reporting measures, revisions to the 340B Drug Discount Program, etc. Proposals are interesting, but will Congress actually do anything? If anything is actually going to pass, it has to get through the Senate.
Read more
Already Enormous False Claims Act Penalties Set to Increase
May 6, 2016 | Blog | By Brian Dunphy, Samantha Kingsbury
The already enormous per-claim penalties under the federal False Claims Act (“FCA”) may nearly double by August 1, 2016, ratcheting up the stakes of FCA cases for health care providers, pharmaceutical and medical device manufacturers, and life sciences companies subject to the FCA.
Read more
Five Days Until The Mintz/ML Strategies Pharmacy Industry Summit
May 5, 2016 | Blog | By Theresa Carnegie
Following our first panel discussing Drug Pricing Challenges and Opportunities, the second panel, which Theresa is moderating involves a subject near and dear to the heart of many of our clients: The New Wave of Value-Based Pricing and Contracting.
Read more
CMS Proposes “Advancing Care Information” Program to Replace Meaningful Use
May 5, 2016 | Blog | By Dianne Bourque
The Medicare Access and CHIP Reauthorization Act (MACRA) proposes a new approach, with new branding labels, to paying clinicians for the value and the quality of care that they provide by replacing a patchwork of existing quality-related programs, including the Electronic Health Records (EHRs) Incentive Programs, also known as “Meaningful Use.”
Read more
Six Days Until The Mintz/ML Strategies Pharmacy Industry Summit
May 4, 2016 | Blog | By Theresa Carnegie
We are thrilled that our inaugural Pharmacy Industry Summit is now less than a week away. The Summit is next Tuesday May 10th, 2016, here in our DC offices. Since we started planning for the Summit many months ago, this hottest of topics that we chose to cover, drug pricing, has become even hotter.
Read more
New Compounding Policies from FDA May Affect Hospital and Health System Pharmacy Operations
May 3, 2016 | Blog | By Joanne Hawana
Last month, the FDA released three draft guidance documents that are expected to have significant implications for traditional pharmacy-based compounding and the distribution of those drug products.
Read more
CMS Releases Proposed Rule for MACRA Implementation – Overview and Merit-Based Incentive Payment Systems (MIPS)
May 3, 2016 | Blog
On April 27, 2016, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule that would put in place key parts of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).
Read more
CMS Increases Oversight of Medicaid Managed Care Contracts
April 28, 2016 | Blog
As noted in a post published yesterday, CMS issued the final rule regarding Medicaid managed care earlier this week. With this rule, CMS is taking a much more active role in overseeing states’ Medicaid managed care contracts.
Read more
Explore Other Viewpoints:
- AI: The Washington Report
- Antitrust
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Artificial Intelligence
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Cannabis
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Corporate Governance (ESG)
- Cross-Border Asset Recovery
- Debt Financing
- Direct Investing (M&A)
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment
- Energy & Sustainability
- Environmental (ESG)
- Environmental Enforcement Defense
- Environmental Law
- Environmental, Social, and Corporate Governance (ESG)
- FDA Regulatory
- False Claims Act
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Growth Equity
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Impacts of a New US Administration
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Pharmacy Benefits and PBM Contracting
- Portfolio Companies
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Probate & Fiduciary Litigation
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Transactions
- Real Estate, Construction & Infrastructure
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Social (ESG)
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- State Attorneys General
- Strategic IP Monetization & Licensing
- Tax
- Technology
- Technology, Communications & Media
- Technology, Communications & Media Litigation
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Value-Based Care
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology